Drug/Small Molecule:
doxycycline

2D structure

Overview

Generic Names: Doxcycline anhydrous; Doxycycline Hyclate; Doxycycline Monohydrate; Doxytetracycline
IUPAC Name: (2Z,4S,4aR,5S,5aR,6R,12aS)-2-(amino-hydroxymethylidene)-4-dimethylamino-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
Trade Names: Alti-Doxycycline; Apo-Doxy; Atridox; Doryx; Doxy 100; Doxy-Caps; Doxy-Lemmon; Doxychel; Doxychel Hyclate; Doxycin; Doxylin; Doxytec; Jenacyclin; Monodox; Novo-Doxylin; Nu-Doxycycline; Oracea; Periostat; Supracyclin; Vibra-Tabs; Vibramycin
PharmGKB Accession Id: PA449415

Description

A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum). [PubChem]

Indication

For the treatment of infections caused by susceptible organisms.

ATC Therapeutic Categories

  • A01AB:Antiinfectives and antiseptics for local oral treatment
  • J01AA:Tetracyclines

Pharmacology and Interactions

Mechanism Of Action

Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis.

Pharmacology

Doxycycline, a long-acting tetracycline derived from oxytetracycline, is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with COPD, and adult periodontitis.

Food Interactions

Avoid alcohol. Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication. Take with a full glass of water Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Protein Binding

>90%

Absorption

Completely absorbed following oral administration.

Half Life

18-22 hours

Toxicity

Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD50=262 mg/kg (I.P. in rat).

Chemical Properties

Chemical Formula:

C22H24N2O8

SMILES Code:

C[C@H]1c2cccc(c2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O.O

(Format: OpenEye Isomeric)

Molecular Weight ( average / monoisotopic )

444.4346 / 444.1533

Curated Information

The following genes are in curated knowledge about this drug.

  Gene Relationship Evidence
Phenotype data available Genotype Data Available Literature annotations available Has annotations
ABCB1
  •   
  •   
  •   
  • FA
  •   
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
HTR1A
  •   
  •   
  •   
  • FA
  •   
Publications

Non-Curated Information

A list of non-curated publications that mention this drug along with other genes is available.

Metabolizing Enzymes

Non-Curated Information

A list of non-curated publications that mention this drug along with other drugs is available.

Drug Interactions

acenocoumarol The tetracycline increases the anticoagulant effect
acitretin Increased risk of intracranial hypertension
aluminium Formation of non-absorbable complexes
amobarbital The anticonvulsant decreases the effect of doxycycline
amoxicillin Possible antagonism of action
ampicillin Possible antagonism of action
anisindione The tetracycline increases the anticoagulant effect
aprobarbital The anticonvulsant decreases the effect of doxycycline
attapulgite Formation of non-absorbable complexes
azlocillin Possible antagonism of action
aztreonam Possible antagonism of action
bacampicillin Possible antagonism of action
bismuth Formation of non-absorbable complexes
butabarbital The anticonvulsant decreases the effect of doxycycline
butalbital The anticonvulsant decreases the effect of doxycycline
butethal The anticonvulsant decreases the effect of doxycycline
calcium Formation of non-absorbable complexes
carbamazepine The anticonvulsant decreases the effect of doxycycline
carbenicillin Possible antagonism of action
clavulanate Possible antagonism of action
cloxacillin Possible antagonism of action
cyclacillin Possible antagonism of action
dicloxacillin Possible antagonism of action
dicumarol The tetracycline increases the anticoagulant effect
digoxin The tetracycline increases the effect of digoxin in 10% of patients
dihydroquinidine barbiturate The anticonvulsant decreases the effect of doxycycline
ethinyl estradiol This anti-infectious agent could decrease the effect of the oral contraceptive
ethotoin The anticonvulsant decreases the effect of doxycycline
etretinate Increased risk of intracranial hypertension
flucloxacillin Possible antagonism of action
fosphenytoin The anticonvulsant decreases the effect of doxycycline
heptabarbital The anticonvulsant decreases the effect of doxycycline
hetacillin Possible antagonism of action
hexobarbital The anticonvulsant decreases the effect of doxycycline
insulin Tetracycline increases the risk of hypoglycemia
insulin-aspart Tetracycline increases the risk of hypoglycemia
insulin-detemir Tetracycline increases the risk of hypoglycemia
insulin-glargine Tetracycline increases the risk of hypoglycemia
insulin-glulisine Tetracycline increases the risk of hypoglycemia
insulin-lispro Tetracycline increases the risk of hypoglycemia
iron Formation of non-absorbable complexes
isotretinoin Increased risk of intracranial hypertension
magnesium Formation of non-absorbable complexes
magnesium oxide Formation of non-absorbable complexes
mephenytoin The anticonvulsant decreases the effect of doxycycline
mestranol This anti-infectious agent could decrease the effect of the oral contraceptive
methohexital The anticonvulsant decreases the effect of doxycycline
methotrexate The tetracycline increases methotrexate toxicity
methylphenobarbital The anticonvulsant decreases the effect of doxycycline
meticillin Possible antagonism of action
mezlocillin Possible antagonism of action
nafcillin Possible antagonism of action
oxacillin Possible antagonism of action
penicillin g Possible antagonism of action
penicillin v Possible antagonism of action
pentobarbital The anticonvulsant decreases the effect of doxycycline
phenobarbital The anticonvulsant decreases the effect of doxycycline
phenytoin The anticonvulsant decreases the effect of doxycycline
piperacillin Possible antagonism of action
pivampicillin Possible antagonism of action
pivmecillinam Possible antagonism of action
primidone The anticonvulsant decreases the effect of doxycycline
quinidine barbiturate The anticonvulsant decreases the effect of doxycycline
rifabutin The rifamycin decreases the effect of doxycycline
rifampin The rifamycin decreases the effect of doxycycline
secobarbital The anticonvulsant decreases the effect of doxycycline
talbutal The anticonvulsant decreases the effect of doxycycline
tazobactam Possible antagonism of action
ticarcillin Possible antagonism of action
warfarin The tetracycline increases the anticoagulant effect
zinc Formation of non-absorbable complexes

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00254
KEGG Compound ID:
C06973
PubChem Compound ID:
5281011
PubChem Substance ID:
154560

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
The PharmGKB is financially supported by the NIH/ NIGMS and is managed at Stanford University (U01GM61374).
©2001-2010 PharmGKB.